ANDA 76968, held by Oxford Pharmaceuticals. Paroxetine Hydrochloride.
As of Nov 21, 2026, ANDA 76968 (Paroxetine Hydrochloride), held by Oxford Pharmaceuticals, was first approved by FDA on Jun 21, 2010, with 2 approved supplements and 0 published complete response letters.
Paroxetine is a selective serotonin reuptake inhibitor (SSRI) indicated in adults for the treatment of: Major Depressive Disorder (MDD) Obsessive Compulsive Disorder (OCD) Panic Disorder (PD) Social Anxiety Disorder (SAD) Generalized Anxiety Disorder (GAD) Posttraumatic Stress Disorder (PTSD) Paroxetine is indicated in adults for the treatment of: Major depressive disorder (MDD) Obsessive compulsive disorder (OCD) Panic disorder (PD) Social anxiety disorder (SAD) Generalized anxiety disorder (GAD) Posttraumatic stress disorder (PTSD)
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 21, 2010 | Original application | Approved | None posted |
| Paroxetine HydrochlorideEQ 10MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Paroxetine HydrochlorideEQ 20MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Paroxetine HydrochlorideEQ 30MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Paroxetine HydrochlorideEQ 40MG BASE · tablet;oral | Paroxetine Hydrochloride | Rx |
| Jun 28, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jun 28, 2023 | Supplement 4Labeling · Standard review | Approved | None posted |
| Jun 21, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters